A Multi-national, Multi-center, Double-blind, Double Dummy, Randomized, Active-controoled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.

Trial Profile

A Multi-national, Multi-center, Double-blind, Double Dummy, Randomized, Active-controoled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jun 2010 Results have been presented at the 17th World Congress of Cardiology.
    • 22 Sep 2009 Actual patient number changed from 919 to 918 as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Actual study completion date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top